Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Combined With FOLFOX4 in Recurrent HCC After Liver Transplantation
NCT05355155Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05355155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355155.